The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) on Thursday recommended granting permission for trials of mixing COVID-19 vaccines–Covaxin and Covishield–said sources. As per sources, the application of the interchangeability study protocol of Covishield and Covaxin was moved by Christian Medical College (CMC) in Vellore.
Subject Expert Committee (SEC) gave nod to Bharat Biotechs Covaxin for phase 2 and 3 human clinical trials on 2 to 18 years. In the ongoing vaccination drive in India, the Covaxin is being used in adults. Covaxin is one of the two vaccines being manufactured in India currently and has been developed by Bharat Biotech.